{"id": "article-19542_0", "title": "Chronic Transplantation Rejection -- Continuing Education Activity", "content": "Transplant rejection can be classified as hyperacute, acute, or chronic. Hyperacute rejection is usually caused by specific antibodies against the graft and occurs within minutes or hours after grafting. Acute rejection occurs days or weeks after transplantation and can be caused by specific lymphocytes in the recipient that recognize human leukocyte antigens in the tissue or organ grafted. Finally, chronic rejection usually occurs months or years after organ or tissue transplantation. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play essential roles in the immunopathogenesis of chronic rejections. This activity reviews the evaluation and management of chronic transplant rejections and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.", "contents": "Chronic Transplantation Rejection -- Continuing Education Activity. Transplant rejection can be classified as hyperacute, acute, or chronic. Hyperacute rejection is usually caused by specific antibodies against the graft and occurs within minutes or hours after grafting. Acute rejection occurs days or weeks after transplantation and can be caused by specific lymphocytes in the recipient that recognize human leukocyte antigens in the tissue or organ grafted. Finally, chronic rejection usually occurs months or years after organ or tissue transplantation. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play essential roles in the immunopathogenesis of chronic rejections. This activity reviews the evaluation and management of chronic transplant rejections and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients."}
{"id": "article-19542_1", "title": "Chronic Transplantation Rejection -- Continuing Education Activity", "content": "Objectives: Identify the pathophysiology of chronic transplant rejection. Describe the typical presentation of a patient with chronic transplant rejection. Explain how to manage chronic transplant rejection. Explain the importance of improving coordination among the interprofessional team to enhance care for patients affected by chronic transplant rejection. Access free multiple choice questions on this topic.", "contents": "Chronic Transplantation Rejection -- Continuing Education Activity. Objectives: Identify the pathophysiology of chronic transplant rejection. Describe the typical presentation of a patient with chronic transplant rejection. Explain how to manage chronic transplant rejection. Explain the importance of improving coordination among the interprofessional team to enhance care for patients affected by chronic transplant rejection. Access free multiple choice questions on this topic."}
{"id": "article-19542_2", "title": "Chronic Transplantation Rejection -- Introduction", "content": "Transplant rejection can\u00a0be classified as hyperacute, acute, or\u00a0chronic. Hyperacute rejection\u00a0is usually caused by specific antibodies against the graft and occurs within minutes or hours after grafting. Acute rejection occurs days or weeks after transplantation and can be caused by specific lymphocytes in the recipient that recognize\u00a0HLA antigens in the tissue or organ\u00a0grafted. Finally, chronic rejection usually occurs months or years after organ or tissue transplantation. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play an essential\u00a0role in the\u00a0immunopathogenesis of chronic rejection.", "contents": "Chronic Transplantation Rejection -- Introduction. Transplant rejection can\u00a0be classified as hyperacute, acute, or\u00a0chronic. Hyperacute rejection\u00a0is usually caused by specific antibodies against the graft and occurs within minutes or hours after grafting. Acute rejection occurs days or weeks after transplantation and can be caused by specific lymphocytes in the recipient that recognize\u00a0HLA antigens in the tissue or organ\u00a0grafted. Finally, chronic rejection usually occurs months or years after organ or tissue transplantation. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play an essential\u00a0role in the\u00a0immunopathogenesis of chronic rejection."}
{"id": "article-19542_3", "title": "Chronic Transplantation Rejection -- Etiology", "content": "The etiology of chronic rejection is incompletely understood.\u00a0Glinton et al. reported that\u00a0a vital determinant of the complication of chronic solid organ allografts\u00a0is by a vascular disease component of the transplanted graft. Their review, however, focused on cardiac transplantation only. In cardiac allograft vasculopathy, histologic evidence suggests that the accumulation and activation of phagocytes can be a contributing factor. Phagocytic cells such as macrophages, monocytes, and immature dendritic cell subsets are found in this type of\u00a0chronic cardiac transplant rejection.\u00a0Furthermore, myeloid phagocytes crosstalk with B and T lymphocytes while also signaling and activating vascular smooth muscle cells and fibroblasts,\u00a0and these\u00a0can cause\u00a0fibrous intimal thickening. [1] Chronic renal allograft rejection has\u00a0been labeled as interstitial fibrosis and tubular atrophy to help reflect the underlying histology and etiology. Chronic rejection\u00a0is now cited as the leading cause of graft rejection.", "contents": "Chronic Transplantation Rejection -- Etiology. The etiology of chronic rejection is incompletely understood.\u00a0Glinton et al. reported that\u00a0a vital determinant of the complication of chronic solid organ allografts\u00a0is by a vascular disease component of the transplanted graft. Their review, however, focused on cardiac transplantation only. In cardiac allograft vasculopathy, histologic evidence suggests that the accumulation and activation of phagocytes can be a contributing factor. Phagocytic cells such as macrophages, monocytes, and immature dendritic cell subsets are found in this type of\u00a0chronic cardiac transplant rejection.\u00a0Furthermore, myeloid phagocytes crosstalk with B and T lymphocytes while also signaling and activating vascular smooth muscle cells and fibroblasts,\u00a0and these\u00a0can cause\u00a0fibrous intimal thickening. [1] Chronic renal allograft rejection has\u00a0been labeled as interstitial fibrosis and tubular atrophy to help reflect the underlying histology and etiology. Chronic rejection\u00a0is now cited as the leading cause of graft rejection."}
{"id": "article-19542_4", "title": "Chronic Transplantation Rejection -- Epidemiology", "content": "The overall incidence and prevalence of chronic allograft nephropathy (CAN) in biopsies of renal allograft tissues depends on the timing and the indication of such graft biopsies. In protocol biopsies, in the first year post-transplantation, it has been reported that the prevalence can be as high as 94% (grade I) and up to 100% after\u00a0ten years.", "contents": "Chronic Transplantation Rejection -- Epidemiology. The overall incidence and prevalence of chronic allograft nephropathy (CAN) in biopsies of renal allograft tissues depends on the timing and the indication of such graft biopsies. In protocol biopsies, in the first year post-transplantation, it has been reported that the prevalence can be as high as 94% (grade I) and up to 100% after\u00a0ten years."}
{"id": "article-19542_5", "title": "Chronic Transplantation Rejection -- Epidemiology", "content": "In the United States, mortality in patients on\u00a0chronic\u00a0hemodialysis is significantly higher in winter months than in the summer. It is unknown whether a seasonal difference exists, however, for mortality or graft failure among kidney transplant recipients. One report showed that there was a significant annual variation of deaths due to graft failures. [2]", "contents": "Chronic Transplantation Rejection -- Epidemiology. In the United States, mortality in patients on\u00a0chronic\u00a0hemodialysis is significantly higher in winter months than in the summer. It is unknown whether a seasonal difference exists, however, for mortality or graft failure among kidney transplant recipients. One report showed that there was a significant annual variation of deaths due to graft failures. [2]"}
{"id": "article-19542_6", "title": "Chronic Transplantation Rejection -- Pathophysiology", "content": "Chronic allograft rejection can be caused by\u00a0antibody-dependent complement activation lesions\u00a0as well as\u00a0cell arteritis leading to\u00a0the development\u00a0of interstitial fibrosis/tubular atrophy (IF/TA). [3] This injury can appear early\u00a0after transplantation. At 1-year post-transplant, greater than 81% of the kidneys have minimal lesions of IF/TA that tend to\u00a0progress over time; these lesions affect greater than 50% of transplanted kidneys with severe lesions at five years.", "contents": "Chronic Transplantation Rejection -- Pathophysiology. Chronic allograft rejection can be caused by\u00a0antibody-dependent complement activation lesions\u00a0as well as\u00a0cell arteritis leading to\u00a0the development\u00a0of interstitial fibrosis/tubular atrophy (IF/TA). [3] This injury can appear early\u00a0after transplantation. At 1-year post-transplant, greater than 81% of the kidneys have minimal lesions of IF/TA that tend to\u00a0progress over time; these lesions affect greater than 50% of transplanted kidneys with severe lesions at five years."}
{"id": "article-19542_7", "title": "Chronic Transplantation Rejection -- Pathophysiology", "content": "The 2011 Banff meeting focused on diagnostic criteria for late-antibody mediated rejection.\u00a0 In this review, there was the recognition of CD4-negative antibody-mediated rejection, in which endothelial activation and NK cells were suggested as\u00a0the primary causes of chronic reaction. [4] Other proposed pathophysiologic mechanisms include: Calcineurin inhibitors (CNI) toxicity Chronic dysfunction of the solid organ\u00a0causing premature graft loss Alloimmunization to minor HLA antigens Production of interferon-gamma and IL-2 by Th1 lymphocytes Secretion of cytokines by endothelial cells", "contents": "Chronic Transplantation Rejection -- Pathophysiology. The 2011 Banff meeting focused on diagnostic criteria for late-antibody mediated rejection.\u00a0 In this review, there was the recognition of CD4-negative antibody-mediated rejection, in which endothelial activation and NK cells were suggested as\u00a0the primary causes of chronic reaction. [4] Other proposed pathophysiologic mechanisms include: Calcineurin inhibitors (CNI) toxicity Chronic dysfunction of the solid organ\u00a0causing premature graft loss Alloimmunization to minor HLA antigens Production of interferon-gamma and IL-2 by Th1 lymphocytes Secretion of cytokines by endothelial cells"}
{"id": "article-19542_8", "title": "Chronic Transplantation Rejection -- Histopathology", "content": "The main histological finding in biopsies of rejected organs\u00a0is arteriosclerosis that causes a progressive luminal narrowing of graft vessels.\u00a0This is typically referred to as a\u00a0vasculopathy or graft vascular disease. This entity is\u00a0often accompanied by graft tissue (parenchymal) fibrosis. [5] For example, livers with chronic rejection show a decreased number of bile ducts on biopsy and obliteration of small arteries. Correspondingly, lung rejection is characterized by bronchiolitis obliterans.\u00a0 The presence of endothelial injury and subsequent inflammation has been suggested as the inciting cause of this vascular dysfunction.", "contents": "Chronic Transplantation Rejection -- Histopathology. The main histological finding in biopsies of rejected organs\u00a0is arteriosclerosis that causes a progressive luminal narrowing of graft vessels.\u00a0This is typically referred to as a\u00a0vasculopathy or graft vascular disease. This entity is\u00a0often accompanied by graft tissue (parenchymal) fibrosis. [5] For example, livers with chronic rejection show a decreased number of bile ducts on biopsy and obliteration of small arteries. Correspondingly, lung rejection is characterized by bronchiolitis obliterans.\u00a0 The presence of endothelial injury and subsequent inflammation has been suggested as the inciting cause of this vascular dysfunction."}
{"id": "article-19542_9", "title": "Chronic Transplantation Rejection -- History and Physical", "content": "Individuals presenting with chronic transplant rejection will have had a previous history of organ or tissue transplantation (for example, kidney, liver, and lung) for any of many chronic medical conditions. The symptoms and signs of rejection depend on the organ transplanted; for instance, a chronic kidney rejection causes fatigue, fever, flu-like symptoms, anuria or decreased urine output, generalized edema, and pain or tenderness at the site of transplantation.\u00a0Other signs and symptoms of organ\u00a0rejection can include: Jaundice Dark urine Itching Nausea and vomiting Abdominal swelling or tenderness Cough, shortness of breath Recurrent infections Arterial hypertension Proteinuria Fatigue Weight gain Premature death Anorexia Anemia Opportunistic neoplasia Pulmonary edema Atherosclerosis", "contents": "Chronic Transplantation Rejection -- History and Physical. Individuals presenting with chronic transplant rejection will have had a previous history of organ or tissue transplantation (for example, kidney, liver, and lung) for any of many chronic medical conditions. The symptoms and signs of rejection depend on the organ transplanted; for instance, a chronic kidney rejection causes fatigue, fever, flu-like symptoms, anuria or decreased urine output, generalized edema, and pain or tenderness at the site of transplantation.\u00a0Other signs and symptoms of organ\u00a0rejection can include: Jaundice Dark urine Itching Nausea and vomiting Abdominal swelling or tenderness Cough, shortness of breath Recurrent infections Arterial hypertension Proteinuria Fatigue Weight gain Premature death Anorexia Anemia Opportunistic neoplasia Pulmonary edema Atherosclerosis"}
{"id": "article-19542_10", "title": "Chronic Transplantation Rejection -- Evaluation", "content": "Various laboratory tests\u00a0can be ordered to test for chronic rejection. These may include\u00a0the following: Twenty-four-hour urine collection Blood chemistry Complete\u00a0blood cell count Electrocardiogram Chest x-ray CT (computed tomography) of the abdomen Abdominal ultrasonography Histological studies HLA typing (This will test for histocompatibility between donor and recipient. The most critical loci are HLA-A, HLA-B, and HLA-DR.) Serology (testing for HIV; hepatitis B and C)", "contents": "Chronic Transplantation Rejection -- Evaluation. Various laboratory tests\u00a0can be ordered to test for chronic rejection. These may include\u00a0the following: Twenty-four-hour urine collection Blood chemistry Complete\u00a0blood cell count Electrocardiogram Chest x-ray CT (computed tomography) of the abdomen Abdominal ultrasonography Histological studies HLA typing (This will test for histocompatibility between donor and recipient. The most critical loci are HLA-A, HLA-B, and HLA-DR.) Serology (testing for HIV; hepatitis B and C)"}
{"id": "article-19542_11", "title": "Chronic Transplantation Rejection -- Evaluation", "content": "In renal transplantation, urinary samples can prove useful to determine rejection.\u00a0 Tubular epithelial cells, casts, oxalate crystals (sand-glass shaped), dirty background, increasing erythrocyturia, mixed cell clusters, lymphocytes, and mitoses all may be observed.", "contents": "Chronic Transplantation Rejection -- Evaluation. In renal transplantation, urinary samples can prove useful to determine rejection.\u00a0 Tubular epithelial cells, casts, oxalate crystals (sand-glass shaped), dirty background, increasing erythrocyturia, mixed cell clusters, lymphocytes, and mitoses all may be observed."}
{"id": "article-19542_12", "title": "Chronic Transplantation Rejection -- Evaluation", "content": "\"Owl-eye\" cells milk-glass nuclei, sometimes with eosinophilic condensation,\u00a0typically characterize cytologic examination of the voided urine in CMV infection. [6] Serological tests can further help in differentiating CMV-infection from allograft rejection.", "contents": "Chronic Transplantation Rejection -- Evaluation. \"Owl-eye\" cells milk-glass nuclei, sometimes with eosinophilic condensation,\u00a0typically characterize cytologic examination of the voided urine in CMV infection. [6] Serological tests can further help in differentiating CMV-infection from allograft rejection."}
{"id": "article-19542_13", "title": "Chronic Transplantation Rejection -- Treatment / Management", "content": "The treatment of organ rejection depends on the type of\u00a0injury and underlying etiology. In chronic kidney rejection, complications including arterial hypertension, pulmonary edema, and uremia should be managed through various therapeutic options, including but not limited to hemodialysis, hemofiltration, and the use of diuretics. As a general statement, most\u00a0infectious causes should be treated with specific, directed antimicrobials.", "contents": "Chronic Transplantation Rejection -- Treatment / Management. The treatment of organ rejection depends on the type of\u00a0injury and underlying etiology. In chronic kidney rejection, complications including arterial hypertension, pulmonary edema, and uremia should be managed through various therapeutic options, including but not limited to hemodialysis, hemofiltration, and the use of diuretics. As a general statement, most\u00a0infectious causes should be treated with specific, directed antimicrobials."}
{"id": "article-19542_14", "title": "Chronic Transplantation Rejection -- Treatment / Management", "content": "In diabetic nephropathy, the albumin to\u00a0creatinine ratio can\u00a0be used to\u00a0guide therapy.\u00a0 If\u00a0this ratio is greater than 3, inhibition\u00a0of the renin-angiotensin system\u00a0is recommended with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB). This therapy should be pursued even in the setting of normal blood pressure\u00a0to help protect the donor's kidney.", "contents": "Chronic Transplantation Rejection -- Treatment / Management. In diabetic nephropathy, the albumin to\u00a0creatinine ratio can\u00a0be used to\u00a0guide therapy.\u00a0 If\u00a0this ratio is greater than 3, inhibition\u00a0of the renin-angiotensin system\u00a0is recommended with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB). This therapy should be pursued even in the setting of normal blood pressure\u00a0to help protect the donor's kidney."}
{"id": "article-19542_15", "title": "Chronic Transplantation Rejection -- Treatment / Management", "content": "Tight glucose control is recommended in the setting of hyperglycemia.\u00a0 In type 1 diabetes mellitus, therapy is typically\u00a0accomplished with insulin, and in\u00a0non-insulin-dependent diabetes mellitus, therapy is\u00a0usually with a biguanide or sulfonylurea. In end-stage rejection, there may be a consideration for retransplantation of the organ or tissues.", "contents": "Chronic Transplantation Rejection -- Treatment / Management. Tight glucose control is recommended in the setting of hyperglycemia.\u00a0 In type 1 diabetes mellitus, therapy is typically\u00a0accomplished with insulin, and in\u00a0non-insulin-dependent diabetes mellitus, therapy is\u00a0usually with a biguanide or sulfonylurea. In end-stage rejection, there may be a consideration for retransplantation of the organ or tissues."}
{"id": "article-19542_16", "title": "Chronic Transplantation Rejection -- Differential Diagnosis", "content": "The differential diagnosis for chronic rejection is broad but includes acute rejection, infection (CMV), medication toxicity (immunosuppressants), posttransplant lymphoproliferative disease, or technical problems with vascular or structural anastomotic complications.", "contents": "Chronic Transplantation Rejection -- Differential Diagnosis. The differential diagnosis for chronic rejection is broad but includes acute rejection, infection (CMV), medication toxicity (immunosuppressants), posttransplant lymphoproliferative disease, or technical problems with vascular or structural anastomotic complications."}
{"id": "article-19542_17", "title": "Chronic Transplantation Rejection -- Pertinent Studies and Ongoing Trials", "content": "The FTY720 (fingolimod) is a novel immunosuppressive agent that has been\u00a0investigated\u00a0in the last few decades. FTY is highly effective in prolonging graft survival in preclinical models of transplantation and multiple sclerosis. FTY720 is an immunomodulator. Its mode of action differs completely from traditional immunosuppressants. It is a new class of drugs named sphingosine 1-phosphate receptor (S1P-R) modulators. [7] [8] In laboratory animals,\u00a0S1P receptor activation with\u00a0fingolimod\u00a0activates anti-inflammatory and anti-apoptotic\u00a0pathways, leading to improved myocardial salvage by reducing cardiac fibrosis. [9]", "contents": "Chronic Transplantation Rejection -- Pertinent Studies and Ongoing Trials. The FTY720 (fingolimod) is a novel immunosuppressive agent that has been\u00a0investigated\u00a0in the last few decades. FTY is highly effective in prolonging graft survival in preclinical models of transplantation and multiple sclerosis. FTY720 is an immunomodulator. Its mode of action differs completely from traditional immunosuppressants. It is a new class of drugs named sphingosine 1-phosphate receptor (S1P-R) modulators. [7] [8] In laboratory animals,\u00a0S1P receptor activation with\u00a0fingolimod\u00a0activates anti-inflammatory and anti-apoptotic\u00a0pathways, leading to improved myocardial salvage by reducing cardiac fibrosis. [9]"}
{"id": "article-19542_18", "title": "Chronic Transplantation Rejection -- Pertinent Studies and Ongoing Trials", "content": "ASP0028, an S1P1/S1P5-selective agonist, with comparable efficacy to FTY720 and wider safety margins than FTY720, showed the efficacy and safety when it was co-administered with suboptimal-dose of tacrolimus in a monkey renal transplantation model. ASP0028 administration remarkably reduced peripheral lymphocytes, including subsets of CD4+/ or CD8+/naive and memory cells, CD4+/Treg cells, and B cells, but not CD4+/ or CD8+/effector memory cells and natural killer (NK) cells. These data support the finding that ASP0028 and tacrolimus prolong renal allograft survival in primates. [7]", "contents": "Chronic Transplantation Rejection -- Pertinent Studies and Ongoing Trials. ASP0028, an S1P1/S1P5-selective agonist, with comparable efficacy to FTY720 and wider safety margins than FTY720, showed the efficacy and safety when it was co-administered with suboptimal-dose of tacrolimus in a monkey renal transplantation model. ASP0028 administration remarkably reduced peripheral lymphocytes, including subsets of CD4+/ or CD8+/naive and memory cells, CD4+/Treg cells, and B cells, but not CD4+/ or CD8+/effector memory cells and natural killer (NK) cells. These data support the finding that ASP0028 and tacrolimus prolong renal allograft survival in primates. [7]"}
{"id": "article-19542_19", "title": "Chronic Transplantation Rejection -- Staging", "content": "The Banff grading system\u00a0is a classification of the severity of chronic renal allograft nephropathy. This was originally\u00a0implemented in 1997\u00a0and updated subsequently in 2005, 2007, 2009, 2013, and 2017. [3] [4] This schema grades disease severity, according to interstitial fibrosis, atrophy, and loss of tubules\u00a0(IF/TA): Grade I:\u00a0Mild fibrosis of the interstitium and mild atrophy of the tubules, either with or without specific glomerular or vascular findings that can suggest chronic allograft nephropathy. Grade II: Moderate interstitial fibrosis (affecting 25% to 50% of the cortical area) and moderate tubular atrophy (involving 26% to 50% of the area of the cortical tubules). Grade III: Severe interstitial fibrosis (affecting greater than 50 percent of the cortical area) and tubular atrophy (involving greater than 50% of the area of the cortical tubules).", "contents": "Chronic Transplantation Rejection -- Staging. The Banff grading system\u00a0is a classification of the severity of chronic renal allograft nephropathy. This was originally\u00a0implemented in 1997\u00a0and updated subsequently in 2005, 2007, 2009, 2013, and 2017. [3] [4] This schema grades disease severity, according to interstitial fibrosis, atrophy, and loss of tubules\u00a0(IF/TA): Grade I:\u00a0Mild fibrosis of the interstitium and mild atrophy of the tubules, either with or without specific glomerular or vascular findings that can suggest chronic allograft nephropathy. Grade II: Moderate interstitial fibrosis (affecting 25% to 50% of the cortical area) and moderate tubular atrophy (involving 26% to 50% of the area of the cortical tubules). Grade III: Severe interstitial fibrosis (affecting greater than 50 percent of the cortical area) and tubular atrophy (involving greater than 50% of the area of the cortical tubules)."}
{"id": "article-19542_20", "title": "Chronic Transplantation Rejection -- Prognosis", "content": "As many\u00a0as one-third of cadaveric kidney transplant recipients suffer graft loss within five years of transplantation. Unfortunately, changes in immunotherapy have proven to be mostly ineffective in changing the prognosis for patients with established chronic allograft nephropathy. Prevention, early diagnosis, management of both comorbidity, and complications of chronic kidney disease can improve the survival of patients with transplant failure.", "contents": "Chronic Transplantation Rejection -- Prognosis. As many\u00a0as one-third of cadaveric kidney transplant recipients suffer graft loss within five years of transplantation. Unfortunately, changes in immunotherapy have proven to be mostly ineffective in changing the prognosis for patients with established chronic allograft nephropathy. Prevention, early diagnosis, management of both comorbidity, and complications of chronic kidney disease can improve the survival of patients with transplant failure."}
{"id": "article-19542_21", "title": "Chronic Transplantation Rejection -- Complications", "content": "The success of organ transplantation depends on the use of immunosuppressive drugs to control the alloimmune response. The most frequent drugs used for kidney transplantation include a cocktail of 3 medications, including a drug that inhibits T-cell activation (cyclosporin, tacrolimus, or sirolimus), an antiproliferative (6-mercaptopurine, or\u00a0mycophenolic acid), and an anti-inflammatory agent (corticosteroids).", "contents": "Chronic Transplantation Rejection -- Complications. The success of organ transplantation depends on the use of immunosuppressive drugs to control the alloimmune response. The most frequent drugs used for kidney transplantation include a cocktail of 3 medications, including a drug that inhibits T-cell activation (cyclosporin, tacrolimus, or sirolimus), an antiproliferative (6-mercaptopurine, or\u00a0mycophenolic acid), and an anti-inflammatory agent (corticosteroids)."}
{"id": "article-19542_22", "title": "Chronic Transplantation Rejection -- Complications", "content": "Chronic organ rejection can be associated with a high mortality rate and\u00a0may result in various complications, including kidney failure, liver failure, chronic pulmonary disease, pancreatic insufficiency, arteriosclerosis, and blood dyscrasias.", "contents": "Chronic Transplantation Rejection -- Complications. Chronic organ rejection can be associated with a high mortality rate and\u00a0may result in various complications, including kidney failure, liver failure, chronic pulmonary disease, pancreatic insufficiency, arteriosclerosis, and blood dyscrasias."}
{"id": "article-19542_23", "title": "Chronic Transplantation Rejection -- Complications", "content": "Other complications include CMV infection and infectious diseases caused by bacterial, viral, fungal, protozoal, or mixed. Excessive immunosuppression can cause the emergence of BK polyomavirus resulting in BK nephropathy and may account for one to ten percent of allograft failure. A late complication of renal transplantation is the recurrence of the original disease (diabetic nephropathy).", "contents": "Chronic Transplantation Rejection -- Complications. Other complications include CMV infection and infectious diseases caused by bacterial, viral, fungal, protozoal, or mixed. Excessive immunosuppression can cause the emergence of BK polyomavirus resulting in BK nephropathy and may account for one to ten percent of allograft failure. A late complication of renal transplantation is the recurrence of the original disease (diabetic nephropathy)."}
{"id": "article-19542_24", "title": "Chronic Transplantation Rejection -- Complications", "content": "The development of malignancy is a late complication of chronic organ rejection. For example, the incidence of lymphoma is approximately 40 times greater in transplant recipients than in the general population. Other tumors that may be observed include skin cancer, Kaposi sarcoma, and lymphoma due to Epstein-Barr virus activation.", "contents": "Chronic Transplantation Rejection -- Complications. The development of malignancy is a late complication of chronic organ rejection. For example, the incidence of lymphoma is approximately 40 times greater in transplant recipients than in the general population. Other tumors that may be observed include skin cancer, Kaposi sarcoma, and lymphoma due to Epstein-Barr virus activation."}
{"id": "article-19542_25", "title": "Chronic Transplantation Rejection -- Deterrence and Patient Education", "content": "Patients must be compliant with immunosuppressive drugs to avoid organ rejection and improve their quality of life. Similarly, patients\u00a0must also comply with the treatment of any underlying comorbidities.", "contents": "Chronic Transplantation Rejection -- Deterrence and Patient Education. Patients must be compliant with immunosuppressive drugs to avoid organ rejection and improve their quality of life. Similarly, patients\u00a0must also comply with the treatment of any underlying comorbidities."}
{"id": "article-19542_26", "title": "Chronic Transplantation Rejection -- Pearls and Other Issues", "content": "The use of immunosuppressants\u00a0in chronic rejection\u00a0does not adequately\u00a0prevent it. High dosages may be used without an observable therapeutic response. This suggests that chronic rejection may involve many other mechanisms rather than only immunological pathways. Until the pathophysiology and immunopathogenesis of this rejection are fully understood, it is difficult to create novel therapeutic interventions to tackle this problem. The better the HLA matching between donor and recipient, the more successful the organ transplant will be and over a longer period.", "contents": "Chronic Transplantation Rejection -- Pearls and Other Issues. The use of immunosuppressants\u00a0in chronic rejection\u00a0does not adequately\u00a0prevent it. High dosages may be used without an observable therapeutic response. This suggests that chronic rejection may involve many other mechanisms rather than only immunological pathways. Until the pathophysiology and immunopathogenesis of this rejection are fully understood, it is difficult to create novel therapeutic interventions to tackle this problem. The better the HLA matching between donor and recipient, the more successful the organ transplant will be and over a longer period."}
{"id": "article-19542_27", "title": "Chronic Transplantation Rejection -- Enhancing Healthcare Team Outcomes", "content": "An interprofessional team educates and manages the patient with chronic rejection. The team consists of primary care, medical and surgical specialists, specialty trained nurses, and pharmacists. Since this condition\u00a0is life-threatening, the health care providers should advise the patient fully about all other treatment options, psychological support, and in extreme circumstances, consideration for an organ or tissue re-transplantation. Nephrology, cardiology, and transplant nurses provide education to patients and their families, monitor patient status, and direct feedback to the team. Pharmacists evaluate prescribed medications, check for drug-drug interactions, and participate in patient education. In this way, the team can improve outcomes. [Level 5]", "contents": "Chronic Transplantation Rejection -- Enhancing Healthcare Team Outcomes. An interprofessional team educates and manages the patient with chronic rejection. The team consists of primary care, medical and surgical specialists, specialty trained nurses, and pharmacists. Since this condition\u00a0is life-threatening, the health care providers should advise the patient fully about all other treatment options, psychological support, and in extreme circumstances, consideration for an organ or tissue re-transplantation. Nephrology, cardiology, and transplant nurses provide education to patients and their families, monitor patient status, and direct feedback to the team. Pharmacists evaluate prescribed medications, check for drug-drug interactions, and participate in patient education. In this way, the team can improve outcomes. [Level 5]"}
{"id": "article-19542_28", "title": "Chronic Transplantation Rejection -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Chronic Transplantation Rejection -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}